248 related articles for article (PubMed ID: 31900171)
1. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
Kreutzman A; Rohon P; Faber E; Indrak K; Juvonen V; Kairisto V; Voglová J; Sinisalo M; Flochová E; Vakkila J; Arstila P; Porkka K; Mustjoki S
PLoS One; 2011; 6(8):e23022. PubMed ID: 21857985
[TBL] [Abstract][Full Text] [Related]
3. Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors.
Hong Y; Wen R; Wu G; Li S; Liu W; Chen Z; Yang Z
Int Immunopharmacol; 2022 Aug; 109():108821. PubMed ID: 35526383
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Hus I; Tabarkiewicz J; Lewandowska M; Wasiak M; Wdowiak P; Kusz M; Legieć M; Dmoszyńska A; Roliński J
Folia Histochem Cytobiol; 2011; 49(1):153-60. PubMed ID: 21526503
[TBL] [Abstract][Full Text] [Related]
5. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
El Eit R; Itani AR; Nassar F; Rasbieh N; Jabbour M; Santina A; Zaatari G; Mahon FX; Bazarbachi A; Nasr R
Cancer; 2019 Aug; 125(16):2818-2828. PubMed ID: 31034603
[TBL] [Abstract][Full Text] [Related]
7. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
8. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
9. IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Huuhtanen J; Ilander M; Yadav B; Dufva OM; Lähteenmäki H; Kasanen T; Klievink J; Olsson-Strömberg U; Stentoft J; Richter J; Koskenvesa P; Höglund M; Söderlund S; Dreimane A; Porkka K; Gedde-Dahl T; Gjertsen BT; Stenke L; Myhr-Eriksson K; Markevärn B; Lübking A; Dimitrijevic A; Udby L; Bjerrum OW; Hjorth-Hansen H; Mustjoki S
J Clin Invest; 2022 Sep; 132(17):. PubMed ID: 36047494
[TBL] [Abstract][Full Text] [Related]
10. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Rohon P; Porkka K; Mustjoki S
Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
Irani YD; Hughes A; Kok CH; Clarson J; Yeung DT; Ross DM; Branford S; Hughes TP; Yong ASM
Br J Haematol; 2023 Sep; 202(6):1127-1136. PubMed ID: 37482935
[TBL] [Abstract][Full Text] [Related]
12. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
13. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
Front Immunol; 2019; 10():2493. PubMed ID: 31695700
[TBL] [Abstract][Full Text] [Related]
14. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
Aswald JM; Lipton JH; Aswald S; Messner HA
Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
[TBL] [Abstract][Full Text] [Related]
15. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
[TBL] [Abstract][Full Text] [Related]
16. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
17. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
18. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
Christiansson L; Söderlund S; Svensson E; Mustjoki S; Bengtsson M; Simonsson B; Olsson-Strömberg U; Loskog AS
PLoS One; 2013; 8(1):e55818. PubMed ID: 23383287
[TBL] [Abstract][Full Text] [Related]
19. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors.
Chopade P; Akard LP
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):710-723. PubMed ID: 30093283
[TBL] [Abstract][Full Text] [Related]
20. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
